Pemvidutide, a glp-1/glucagon dual receptor agonist, significantly reduces liver fat, fibro-inflammation, and body weight in patients with non-alcoholic fatty liver disease: a 24-week multicenter, randomized, double-blind, placebo-controlled trial
The DOI matches its Crossref record.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“After 24 weeks, the dual GLP-1/GCG agonists, efinopegdutide and pemvidutide, reduced liver fat by up to 73% and 76%, respectively, in participants with MASLD14,15.”
From Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial (2024) · cites this paper as [15]
Citations
Cites
Still being checked.
Cited by
Sanyal, A. J., Kaplan, L. M., Frias, J. P., Brouwers, B., Wu, Q., Thomas, M. K., Harris, C., Schloot, N. C., Du, Y., Mather, K. J., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03018-2 · Cited by 315
Incretin-based investigational therapies for the treatment of MASLD/MASH
Brouwers, B., Rao, G., Tang, Y., Rodríguez, Á., Glass, L. C., & Hartman, M. L. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111675 · Cited by 40
Goldenberg, R. M., Gilbert, J. D., Manjoo, P., Pedersen, S. D., Woo, V. C., & Lovshin, J. A. (2024) · Obesity Reviews · doi:10.1111/obr.13663 · Cited by 27
Chrysavgis, L., Kazanas, S., Bafa, K., Rozani, S., Koloutsou, M. E., & Cholongitas, Ε. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073832 · Cited by 26
Metadata
- Authors
- Harrison, S., Tomah, S., Suschak, J., Roberts, S., Yang, J., He, L., Georges, B., Rodwell-Green, L., Brown, R., Harris, M. S., & Browne, S.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2023-06
- Volume
- 78
- Pages
- S54-S55
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W4384947028
- Cited by
- 4
- References
- 0
- Citations by year
- 2024: 3 · 2023: 1
- FWCI
- 0.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- Journal of Hepatology (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- non-alcoholic fatty liver disease, liver fat reduction, liver fibrosis, liver inflammation, weight loss
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pemvidutide, a glp-1/glucagon dual receptor agonist, significantly reduces liver fat, fibro-inflammation, and body weight in patients with non-alcoholic fatty liver disease: a 24-week multicenter, randomized, double-blind, placebo-controlled trial. https://app.cochat.ai/papers/10.1016/s0168-8278(23)00517-2
- The paper
- Harrison, S., Tomah, S., Suschak, J., Roberts, S., Yang, J., He, L., Georges, B., Rodwell-Green, L., Brown, R., Harris, M. S., & Browne, S. (2023). Pemvidutide, a glp-1/glucagon dual receptor agonist, significantly reduces liver fat, fibro-inflammation, and body weight in patients with non-alcoholic fatty liver disease: a 24-week multicenter, randomized, double-blind, placebo-controlled trial. Journal of Hepatology. https://doi.org/10.1016/s0168-8278(23)00517-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.